Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results
I'm LongbridgeAI, I can summarize articles.AgomAb Therapeutics reported positive Phase 1 data for its inhaled IPF drug AGMB-447, showing favorable safety and robust target engagement. Consequently, the company has submitted a Clinical Trial Application for a Phase 2 study (INSPIRIA) involving approximately 120 patients, with plans to start in late 2026. The trial aims to assess lung function improvements. Analysts maintain a 'Buy' rating on AGMB stock with a $28 price target.
An update from AgomAb Therapeutics NV ADR ( (AGMB) ) is now available.
On September 14, 2026, Agomab Therapeutics reported topline Phase 1 data for AGMB‑447 in patients with idiopathic pulmonary fibrosis, showing a generally favorable safety and tolerability profile at 4.5 mg twice daily via inhalation. The study also confirmed low systemic but high pulmonary exposure and robust ALK5 target engagement, with bronchoalveolar lavage levels and pSMAD3 reduction consistent with prior results in healthy participants.
The company disclosed that it has submitted a Clinical Trial Application for INSPIRIA, a 24‑week Phase 2 randomized, double‑blind, placebo‑controlled study of AGMB‑447 in about 120 IPF patients, and plans to start the trial in the second half of 2026. By moving AGMB‑447 into Phase 2 and designing the study to assess lung function via forced vital capacity on top of standard of care, Agomab is advancing a potentially differentiated inhaled anti‑fibrotic therapy in a market where current treatments only slow disease progression and carry significant tolerability issues for patients.
The most recent analyst rating on (AGMB) stock is a Buy
with a $28.00 price target.
To see the full list of analyst forecasts on AgomAb Therapeutics NV ADR stock,
see the AGMB Stock Forecast page.
More about AgomAb Therapeutics NV ADR
Agomab Therapeutics NV is a clinical-stage biopharmaceutical company headquartered in Antwerp, Belgium, specializing in novel disease‑modifying therapies for fibro‑inflammatory conditions with high unmet medical need. Its pipeline, including the inhaled ALK5 inhibitor AGMB‑447 for idiopathic pulmonary fibrosis, is built around targeting established fibrotic pathways with organ‑restricted approaches to enhance efficacy while reducing systemic safety risks.
The company focuses on developing treatments that locally modulate fibrosis and inflammation to restore organ function, positioning itself in the competitive respiratory and fibrotic disease space. By emphasizing lung‑restricted delivery for IPF and similar indications, Agomab aims to offer safer, more tolerable options compared with existing systemic therapies, which often slow but do not halt disease progression and can lead to discontinuation due to side effects.
Average Trading Volume: 123,051
Technical Sentiment Signal: Strong Buy
Current Market Cap: $643.2M